Piper Sandler Reiterates Overweight on Legend Biotech, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Legend Biotech (NASDAQ:LEGN) and maintained a $90 price target.
June 17, 2024 | 5:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst Edward Tenthoff has reiterated an Overweight rating on Legend Biotech and maintained a $90 price target, indicating continued confidence in the company's growth prospects.
The reiteration of an Overweight rating and a maintained price target of $90 by a reputable analyst suggests strong confidence in Legend Biotech's future performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100